Clinical trials
Advanced Malignant Tumors clinical trials
Below are recruiting advanced malignant tumors clinical trials, each written for real people, not researchers. We’re tracking 1,034 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06589401RecruitingPhase 1
Oral paclitaxel for advanced solid tumors
This trial tests an oral form of paclitaxel for people with advanced solid tumors, including breast cancer. It aims to see if swallowing the drug is safe and effective when standard treatments no longer work.
Barcelona, CataloniaAges 18 years+ - NCT06968572RecruitingPhase 1
New drug for MTAP-deleted solid tumors
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
Guiyang, GuizhouAges 18 years+ - NCT07274085RecruitingPhase 1
Study of HDM2017 for advanced solid tumors
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06265688RecruitingPhase 1
First study of CX-2051 for advanced solid tumors
This study is testing a new drug called CX-2051 for people with advanced solid tumors that have not responded to standard treatments. The drug is a type of targeted therapy that delivers chemotherapy directly to cancer cells, and the goal is to see if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07231081RecruitingPhase 1
TX103 CAR-T cells for advanced solid tumors
This trial tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have a specific protein (B7-H3). The goal is to see if these modified immune cells can shrink tumors or slow their growth.
BeijingAges 18–75 - NCT06874335RecruitingPhase 1
A study of BHV-1530 for advanced solid tumors
This trial tests a new drug, BHV-1530, either alone or with another drug called cemiplimab, for people with certain advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it's safe and effective.
Newport Beach, CaliforniaAges 18 years+ - NCT06940349RecruitingPhase 1/Phase 2
Palbociclib and sunitinib for advanced solid tumors
This study tests a combination of two oral drugs—palbociclib and sunitinib—for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these drugs together can help shrink or slow the growth of the cancer.
Petah TikvaAges 18 years+ - NCT05689853RecruitingPhase 1/Phase 2
Testing two targeted cancer drugs for advanced solid tumors
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
Beijing, Beijing MunicipalityAges 18–75 - NCT06603844RecruitingPhase 1/Phase 2
Study of CRB-601-01 for advanced solid tumors
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT07467629RecruitingPhase 1
Study of QLS5212 for people with advanced solid tumors
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
TaiyuanAges 18 years+ - NCT07098052RecruitingPhase 1
Study of HDM2020 for advanced solid tumors
This trial is testing a new drug called HDM2020 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07487597RecruitingEarly Phase 1
Engineered T cell therapy for ALPP-positive advanced solid tumors
This trial tests a new type of immune cell therapy designed to target and attack cancer cells that have a specific marker called ALPP. It is for people with advanced solid tumors who have not responded to or cannot have standard treatments.
Nanjing, JiangsuAges 18–70 - NCT07069062RecruitingPhase 1/Phase 2
Study of HY0001a for Advanced Solid Tumors
This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06490068RecruitingPhase 2
LTC004 with toripalimab for immunotherapy-resistant solid tumors
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
BeijingAges 18–75 - NCT06342336RecruitingPhase 1
HS-IT101 injection for advanced solid tumors
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
Beijing, Beijing MunicipalityAges 3 weeks–2 months - NCT07265622RecruitingPhase 1/Phase 2
Study of 7MW4911 for advanced solid tumors
This trial tests a new drug called 7MW4911 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a tumor that expresses a certain protein (CDH17).
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Duarte, CaliforniaAges 18 years+ - NCT06038461RecruitingPhase 1/Phase 2
Surufatinib with chemo for advanced neuroendocrine tumors
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT03667170RecruitingPhase 2
Study drug for certain colon cancers with MSI-H or dMMR
This Phase 2 trial tests KN035 in people with advanced or spread-out tumors that have specific genetic markers (MSI-H or dMMR). If you qualify, the study team will look at how well the drug works and how it affects side effects in that group.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03943004RecruitingPhase 1
Study drug DFP-14927 for advanced solid tumors
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT05103683RecruitingPhase 1
First-time test of TORL-1-23 for advanced solid tumors
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
Fullerton, CaliforniaAges 18 years+ - NCT05150691RecruitingPhase 1/Phase 2
Early study of an HER2 drug in advanced solid tumors
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
Cerritos, CaliforniaAges 18 years+ - NCT05532696RecruitingPhase 1/Phase 2
Testing ABT-101 for advanced solid tumors and HER2-mutant lung cancer
This study tests ABT-101, a new experimental treatment, in people with advanced solid tumors. A second part specifically looks at people with non-small cell lung cancer (NSCLC) that has HER2 mutations, to see how well the treatment works and how safe it is.
TaichungAges 18 years+ - NCT05683886RecruitingPhase 2
Study KC1036 for advanced thymus tumors after chemotherapy
This trial tests KC1036 in people with advanced thymoma or thymic carcinoma whose cancer came back or spread after their first standard chemotherapy. It may offer a new treatment option when earlier treatment no longer worked.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant tumors?
- Yes. Clin2 currently lists 1,034 recruiting advanced malignant tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.